{"article_title": "China Bribery Probe, Dismal Advair Sales Leave Glaxo Shares Gasping", "article_keywords": ["advair", "probe", "sales", "shares", "leave", "bribery", "dismal", "glaxo", "china", "gasping"], "article_url": "http://www.forbes.com/sites/brucejapsen/2014/07/23/china-bribery-probe-dismal-advair-sales-leave-gsk-shares-gasping/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Bruce Japsen", "og": {"site_name": "Forbes", "description": "British drug giant GlaxoSmithkline (GSK) this morning slashed its earnings expectations for the year, citing currency fluctuations and deteriorating sales of its respiratory drug Advair, particularly in light of moves in the U.S. by insurers unwilling to pay for the more expensive brand name. The price of Glaxo's shares dipped by [...]", "title": "China Bribery Probe, Dismal Advair Sales Leave Glaxo Shares Gasping", "url": "http://www.forbes.com/sites/brucejapsen/2014/07/23/china-bribery-probe-dismal-advair-sales-leave-gsk-shares-gasping/", "image": "http://blogs-images.forbes.com/brucejapsen/files/2014/07/98d336da0f13a2dece939a6a784d8f60_7403.jpg", "updated_time": "2014-07-23T13:54:44-04:00", "type": "article"}, "twitter": {"description": "British drug giant GlaxoSmithkline (GSK) this morning slashed its earnings expectations for the year, citing currency fluctuations and deteriorating sales of its respiratory drug Advair, particularly in light of moves in the U.S. by insurers unwilling to pay for the more expensive brand name. The price of Glaxo's shares dipped by [...]", "creator": "@brucejapsen", "image": "http://blogs-images.forbes.com/brucejapsen/files/2014/07/98d336da0f13a2dece939a6a784d8f60_7403.jpg", "title": "China Bribery Probe, Dismal Advair Sales Leave Glaxo Shares Gasping", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Powering Productivity,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy,Advair,asthma,China,Express Scripts,Glaxo,GlaxoSmithkline", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/business", "section": "Business", "modified": "2014-07-23", "published": "2014-07-23", "id": "blogAndPostId/blog/post/2125-7403"}, "news_keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Powering Productivity,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy,Advair,asthma,China,Express Scripts,Glaxo,GlaxoSmithkline", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "British drug giant GlaxoSmithkline (GSK) this morning slashed its earnings expectations for the year, citing currency fluctuations and deteriorating sales of its respiratory drug Advair, particularly in light of moves in the U.S. by insurers unwilling to pay for the more expensive brand name. The price of Glaxo's shares dipped by [...]"}, "_id": "\"57477af36914bd0286fd4175\"", "article_summary": ""}